9 Meters Biopharma, Inc. (NMTRQ) Análisis de Acciones

9 Meters Biopharma, Inc. (NMTRQ) Resumen de Asistencia Médica y Tuberías

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on rare digestive diseases, including short bowel syndrome, and gastrointestinal conditions. Its lead product, Vurolenatide, is in Phase 3 trials. The company filed for Chapter 7 liquidation in 2023, impacting its future operations and potential for drug development within the competitive biotechnology sector.

Tesis de Inversión

The investment thesis for 9 Meters Biopharma, Inc. is significantly impacted by its Chapter 7 liquidation filing in July 2023. With a market capitalization of $0.00B and a negative ROE of -375.6%, the company's financial viability is uncertain. The high beta of 10.00 indicates extreme volatility. While Vurolenatide was in Phase 3 trials, the bankruptcy proceedings cast doubt on its future development and potential revenue generation. Investors should be aware of the high risks associated with companies undergoing liquidation, including the potential loss of investment.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

• Market Cap of $0.00B indicates the company's distressed financial state.
• ROE of -375.6% reflects significant losses and financial instability.
• Free Cash Flow of $-0.00B highlights the company's inability to generate positive cash flow.
• Beta of 10.00 indicates extremely high volatility compared to the market average.
• Chapter 7 bankruptcy filing on July 17, 2023, signals the company's intent to liquidate its assets.

Competidores y Pares

Fortalezas

• Proprietary drug candidates in clinical development.
• Focus on rare and unmet medical needs.
• Licensing agreements with other companies.
• Experienced management team in drug development.

Debilidades

• Chapter 7 bankruptcy filing.
• Limited financial resources.
• High dependence on clinical trial outcomes.
• Negative ROE and Free Cash Flow.

Catalizadores

• Ongoing: Potential for asset sales during liquidation proceedings.
• Ongoing: Legal proceedings related to bankruptcy.
• Ongoing: Potential for restructuring or acquisition of assets.

Riesgos

• Ongoing: Chapter 7 bankruptcy leading to complete loss of investment.
• Potential: Delisting from the OTC market.
• Potential: Legal claims from creditors.
• Potential: Loss of intellectual property rights.
• Potential: Negative impact on reputation and future business prospects.

Oportunidades de crecimiento

• Advancement of Vurolenatide: Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1), was in Phase 3 clinical trials for treating short bowel syndrome (SBS). Successful completion of these trials and subsequent regulatory approval could have addressed a significant unmet need in the SBS market, estimated to reach $2.3 billion by 2028. However, the company's bankruptcy filing jeopardizes this potential growth driver.
• Development of NM-136: NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders, represented a potential expansion into a large and growing market. The global obesity market is projected to reach $40 billion by 2030, driven by increasing prevalence of obesity and related comorbidities. However, the bankruptcy filing casts doubt on the continued development of this asset.
• Expansion of NM-102: NM-102, a small molecule peptide designed to prevent antigens from trafficking into systemic circulation, could have addressed various autoimmune and inflammatory conditions. The market for autoimmune disease treatments is substantial, estimated at $60 billion globally. Further development of NM-102 could have opened new avenues for growth, but the bankruptcy filing impacts its future.
• Partnered Product Larazotide: Larazotide, an 8-amino acid peptide in Phase 2 clinical trials for multi-system inflammatory syndrome, represented a partnered opportunity. Positive trial results and subsequent commercialization could have generated revenue through royalties or milestone payments. However, the bankruptcy filing introduces uncertainty regarding the future of this partnership and the development of Larazotide.
• Licensing Agreements: 9 Meters Biopharma had licensing agreements with companies like Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. These agreements could have provided access to novel technologies and therapeutic candidates, potentially fueling future growth. However, the bankruptcy filing may impact the validity and continuation of these agreements.

Oportunidades

• Potential for successful clinical trial results.
• Partnerships for further drug development.
• Market growth in rare digestive diseases.
• Advancements in biotechnology and drug delivery.

Amenazas

• Regulatory hurdles and approval delays.
• Competition from other pharmaceutical companies.
• Clinical trial failures.
• Economic downturn impacting healthcare spending.

Ventajas competitivas

• Proprietary drug candidates targeting specific unmet needs.
• Intellectual property protection through patents and exclusivity.
• Clinical trial data supporting efficacy and safety.
• Licensing agreements providing access to novel technologies.

Acerca de NMTRQ

9 Meters Biopharma, Inc. was a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for rare and unmet needs in digestive diseases. Founded with the mission to improve the lives of patients with gastrointestinal disorders, the company focused on developing treatments for conditions like short bowel syndrome (SBS) and other debilitating digestive ailments. Its lead product candidate, Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1), reached Phase 3 clinical trials for the treatment of SBS, representing a significant milestone in its development pipeline. In addition to Vurolenatide, 9 Meters Biopharma was also developing NM-136, a humanized monoclonal antibody for obesity and related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. The company also had a partnered product, Larazotide, an 8-amino acid peptide in Phase 2 trials for multi-system inflammatory syndrome. 9 Meters Biopharma operated through licensing agreements with companies like Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. Headquartered in Raleigh, North Carolina, the company's operations came to a halt when it filed a voluntary petition for liquidation under Chapter 7 bankruptcy on July 17, 2023.

Qué hacen

• Develops treatments for rare digestive diseases.
• Focuses on gastrointestinal conditions with unmet needs.
• Develops therapies for debilitating disorders.
• Lead product candidate was Vurolenatide for short bowel syndrome.
• Developing NM-136 for obesity and obesity-related disorders.
• Developing NM-102 to prevent antigens from trafficking into systemic circulation.
• Developing NM-003 for prevention of acute graft versus host disease.
• Partnered product Larazotide for multi-system inflammatory syndrome.

Modelo de Negocio

• Develops pharmaceutical products through internal research and development.
• Out-licenses or partners with other companies for development and commercialization.
• Generates revenue through potential future sales of approved drugs.
• Relies on licensing agreements for technology and product development.

Contexto de la Industria

9 Meters Biopharma operated within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant risks of clinical trial failures. Companies in this sector often focus on niche markets and rare diseases to gain regulatory advantages and market exclusivity. However, the company's bankruptcy filing reflects the challenges faced by smaller biotech firms in securing funding and navigating the complexities of drug development. Competitors like ADYX and BIMI operate in similar therapeutic areas, highlighting the competitive pressure in the market.

Clientes Clave

• Patients with rare digestive diseases.
• Healthcare providers treating gastrointestinal conditions.
• Hospitals and clinics specializing in digestive disorders.
• Pharmaceutical companies through licensing and partnership agreements.

Finanzas

Gráfico e información

Últimas noticias

No hay noticias recientes disponibles para NMTRQ.

Consenso de analistas

MoonshotScore

NMTRQ Preguntas Frecuentes sobre Acciones de Healthcare

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Popular Stocks